Current and Next Generation Antimitotic Therapies in Cancer

摘要: The partitioning of chromosomal and nonchromosomal materials during mitotic cell division represents a dramatic cellular reorganization, even minor disruptions in the proteins that regulate progression can adversely impact viability. Mitotic thus an especially vulnerable point life cycle highly proliferative cancer cells. Perhaps unsurprisingly then, antimitotic agents, specifically those targeting microtubules, are among oldest most widely used classes drugs chemotherapeutic arsenal for patient care, with close to two decades clinical use. complexities associated including large numbers this event continue be better elucidated. Along improved understanding come additional opportunities disrupt apparatus treatment beyond direct microtubule perturbing agents. A number enzyme being considered this, kinases, kinesins, GTPases, ubiquitin-like modifiers, ubiquitin specific proteases (USPs) others. These new approaches disrupting machinery offer several potential advantages over traditional antimicrotubule agents; narrower spectrum on-target toxicities, more manageable side effects, distinct range sensitive cancers promise outcome combination other therapeutic modalities.